| Literature DB >> 35400877 |
Niramya J Pathak1, Pavan P Surwase1, U S Karthik1, Abhijit P Patil1, Abhijit M Konnur1, Shailesh M Soni1, Abhishek G Singh1, Arvind P Ganpule1, Ravindra B Sabnis1, Mahesh R Desai1.
Abstract
Introduction: COVID-19 pandemic is associated with secondary opportunistic fungal infections. These have an aggressive course with a high mortality rate. We present our experience of seven cases of post-COVID-19 fungal pyelonephritis.Entities:
Year: 2022 PMID: 35400877 PMCID: PMC8992715 DOI: 10.4103/iju.iju_31_22
Source DB: PubMed Journal: Indian J Urol ISSN: 0970-1591
Details of patients with post COVID-19 fungal pyelonephritis
| Parameter | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 |
|---|---|---|---|---|---|---|---|
| Age (years) | 59 | 35 | 63 | 35 | 20 | 34 | 48 |
| Gender | Male | Male | Male | Male | Female | Male | Male |
| Comorbidities | DM, HTN | None | None | None | None | None | None |
| COVID19 severity as per NIH criteria | Severe | Mild | Severe | Severe | Asymptomatic | Severe | Asymptomatic |
| COVID 19 treatment with corticosteroids | Yes, methylprednisolone | No | Yes, prednisolone | Yes, prednisolone | No | Yes | No |
| Administration of anticoagulant | Yes | No | Yes | Yes | No | Yes | No |
| Administration of anti IL6 monoclonal antibodies | No | No | Yes, tocilizumab | No | No | No | No |
| Administration of supplemental oxygen | Yes | No | Yes | Yes | No | Yes | No |
| Duration between COVID 19 and pyelonephritis (days) | 30 | 60 | 55 | 20 | - | 5 | - |
| Presentation of pyelonephritis | Flank pain and fever | Flank pain and fever | Flank pain and fever | Flank pain and fever | Flank pain and vomiting | Flank pain and pyuria | Flank pain and fever |
| D-dimer (mcg/ml) | 2.1 | 3.3 | 5.5 | 4.9 | 5.4 | 8.3 | 5.8 |
| C reactive protein (mg/L) | 56 | 296 | 141 | 74.9 | 166.4 | 99 | 10.2 |
| Total leukocyte counts | 30300 | 35500 | 15500 | 41600 | 22600 | 14800 | 15900 |
| Creatinine (mg/dl) | 1.9 | 2.04 | 1.87 | 1.07 | 1.26 | 0.76 | 1.32 |
| Urine/fungal culture | Sterile | Aspergillus | Candida Tropicalis | Saccharomyces, Pseudomonas | Sterile | Mucor-mycosis | Sterile |
| USG KUB with | Left bulky kidney with Decreased peripheral vascularity | Left bulky kidney with Decreased peripheral vascularity | Left bulky kidney with Decreased peripheral vascularity | No vascularity | No vascularity to mid and lower pole | Left kidney bulky, hypo-echoic areas, peri-nephric abscess | Left kidney no vascularity |
| CT KUB | Multiple hypodense areas and perinephric fat stranding | Multiple hypodense areas and perinephric fat stranding | Multiple hypodense areas and perinephric fat stranding | Main renal arterial thrombosis | Anterior segmental artery thrombosis | Multiple hypodense areas and renal and peri-nephric abscess | Main arterial thrombosis |
| Laterality | Left | Left | Left | Left | Left | Left | Left |
| Presence of hydronephrosis | Yes | No | Yes | No | No | No | Yes |
| Double J stent/Percutaneous nephrostomy | Yes | No | Yes | No | No | No | Yes |
| Duration between hospitalization and nephrectomy (days) | 10 | 4 | 11 | 7 | 3 | 4 | 2 |
| Nephrectomy approach | Open | Open | Laparoscopic | Open | Open | Open | Lap |
| Final HPE | Necrotizing Fungal inflammation | Necrotizing Fungal inflammation | Necrotizing Fungal inflammation | Necrotizing Fungal inflammation | Necrotizing Fungal inflammation | Necrotizing fungal inflammation | Necrotizing fungal inflammation |
| Fungal tissue culture | Aspergillus | Aspergillus | No growth | Mucormycosis | Mucormycosis | Mucormycosis | Mucormycosis |
| Antifungal type and route | Fluconazole – IV | Amphotericin B – IV, Posaconazole - Oral | Fluconazole - IV | Amphotericin B – IV, Posaconazole - Oral | Voriconazole - Oral | Amphotericin – IV, Posaconazole - Oral | Amphotericin – IV, Posaconazole - Oral |
| Postoperative complications | - | - | Reexploration for reactive bleeding | Reexploration for reactive bleeding | - | Local wound discharge needing debridement and drain placement | Local wound discharge needing debridement and drain placement |
| Duration of hospitalization | 4 | 10 | 30 | 40 | 7 | 44 | 42 |
| Duration from admission to death (days) | 4 | - | 30 | - | 7 | - | - |
| Outcome | Died | Improved | Died | Improved | Died | Improved | Improved |
DM=Diabetes Mellitus, HTN=Hypertension, COVID 19=Coronavirus disease 2019. COVID 19=Coronavirus disease 2019, CT=Computed tomography, USG=Ultrasonography, KUB=Kidney, Ureter and Bladder, HPE=Histopathological Examination
Figure 1(a) Color Doppler ultrasonography image of normal right kidney. (b) Color Doppler ultrasonography image of hypoechoic, enlarged left kidney with absent flow in left renal artery suggestive of thrombosis. (c and d) Coronal and axial views on plain computed tomography kidney ureter bladder showing enlarged right kidney with extensive perinephric fat stranding with thickening of Gerota's fascia suggestive of right pyelonephritis. (e and f) Axial and coronal views on computed tomography angiography showing enlarged left kidney, marked perinephric fat stranding, and no contrast filling seen in mid and distal segment of left renal artery with no contrast enhancement suggestive of left renal artery thrombosis with renal infarct
Figure 2(a) Gross external image of left kidney specimen with segment of ureter weighing 287 g and measuring 13 cm × 6.5 cm × 6 cm. Capsule could not be stripped off. Dark and dusky external appearance of kidney noted. (b) Bisected specimen of kidney mentioned in image A, showing mildly dilated pelvicalyceal system and necrotic areas in kidney. (c) Bisected specimen of kidney of another patient showing mildly dilated pelvicalyceal system areas of necrosis and hemorrhage and loss of corticomedullary differentiation. (d) Bisected specimen of kidney of another patient showing mildly dilated pelvicalyceal system with multiple necrotic foci in mid and lower pole of left kidney with loss of corticomedullary differentiation
Figure 3(a) HPE image showing fibrin platelet thrombi in arteriole- ×400. (b) HPE image showing changes of endotheliitis- ×400. (c) Lactophenol blue stain for fungi from nephrectomy specimen showing Aspergillus Species- ×400. (d) Grocott-Gomori Methenamine Silver (GMS) stain for fungi from nephrectomy specimen showing fungal septate hyphae- ×400. (e) GMS stain from nephrectomy specimen of another patient showing fungal septate hyphae- ×400